key: cord-0880741-80t26wcr authors: Schrader, Sarah M.; Botella, Hélène; Jansen, Robert; Ehrt, Sabine; Rhee, Kyu; Nathan, Carl; Vaubourgeix, Julien title: Multiform antimicrobial resistance from a metabolic mutation date: 2021-08-27 journal: Sci Adv DOI: 10.1126/sciadv.abh2037 sha: 0a6802c15c084571aaa2472da703d5b18f5cfedf doc_id: 880741 cord_uid: 80t26wcr A critical challenge for microbiology and medicine is how to cure infections by bacteria that survive antibiotic treatment by persistence or tolerance. Seeking mechanisms behind such high survival, we developed a forward-genetic method for efficient isolation of high-survival mutants in any culturable bacterial species. We found that perturbation of an essential biosynthetic pathway (arginine biosynthesis) in a mycobacterium generated three distinct forms of resistance to diverse antibiotics, each mediated by induction of WhiB7: high persistence and tolerance to kanamycin, high survival upon exposure to rifampicin, and minimum inhibitory concentration–shifted resistance to clarithromycin. As little as one base change in a gene that encodes, a metabolic pathway component conferred multiple forms of resistance to multiple antibiotics with different targets. This extraordinary resilience may help explain how substerilizing exposure to one antibiotic in a regimen can induce resistance to others and invites development of drugs targeting the mediator of multiform resistance, WhiB7. Antibiotics revolutionized the practice of medicine by offering a cure for many infectious diseases, enhancing the survival of prema ture newborns, improving the success of surgery, and permitting immunosuppressive treatments of malignancies and autoimmune conditions. However, less than a century after the widespread adop tion of antibiotics, these gains are threatened by antimicrobial resist ance (AMR)-a term used here to refer to the ability of microbial pathogens to avoid or delay death upon exposure to antimicro bial compounds that were expected to kill them (1) . An estimated 700,000 people die each year from antimicrobialresistant infections (2) , and by 2050, deaths due to AMR are projected to reach a stag gering 10.5 million per year-more than five times COVID19's global toll in the year 2020. A large proportion of AMR deathsmore than a quarter-are due to drugresistant tuberculosis (TB). TB is caused primarily by Mycobacterium tuberculosis (Mtb) and was the leading cause of death due to a single infectious agent before being overtaken by COVID19 in 2020. Drugsensitive TB can be cured in 85% of cases by treatment with a combination of four drugs for 2 months followed by two of the four for an additional 4 months, but for drugresistant TB, treatment options are generally much longer, more toxic, and less effective, with success rates of only 39 to 57% depending on the number of drugs to which the bacteria are resistant (3) . Antibiotic resistance on the part of Mtb and other major human pathogens can manifest in at least three different ways (Fig. 1) . First, minimum inhibitory concentration (MIC)-shifted resistance occurs when the minimum concentration of antibiotic required to stop growth of a clonal bacterial population is increased. A second manifestation, tolerance, refers to a reduced rate of killing for an entire bacterial pop ulation upon antibiotic exposure. Last, a biphasic kill curve reflecting a reduced rate of killing for a subpopulation is the hallmark of per sistence, which results from phenotypic heterogeneity within a clonal population. This heterogeneity can potentially be epigenetic (4), transcriptional (5) , posttranscriptional (6) , translational (7) , post translational (8) , or metabolic (9) and can also arise from biased par titioning of cellular components during division (10, 11) . In unstressed conditions such as during logarithmic growth in vitro, most bacterial populations contain a small proportion of stochastically generated persister cells [for example, on the order of 10 −6 for Staphylococcus pyogenes (12) ]. Resistance relative to this basal level of persistence can therefore manifest as an increased proportion of persister cells, known as high persistence (13) . A cell that survives antibiotic expo sure through tolerance or persistence will give rise in the absence of the antibiotic to a population that will exhibit the same rate of killing or proportion of persisters upon reexposure to the same drug under the same conditions ( Fig. 1) , and neither tolerance nor persistence leads to an increase in the MIC for populations derived from the tol erant or persistent cells. MICshifted resistance, tolerance, and high persistence can each result from either acquisition of heritable muta tions or stably retained genes (genetic resistance) or conditional in duction of diverse, incompletely understood resistance mechanisms in bacteria that are genetically identical to those that are not resistant (phenotypic resistance). Standard clinical assays used to assess antibiotic resistance do not evaluate tolerance or high persistence. However, these types of re sistance have major clinical consequences, such as long treatment times for TB (14, 15) and recurrence of disease after conclusion of antibiotic therapy for many infections (16, 17) . In addition, pools of tolerant and persistent cells foster the emergence of genetic MIC shifted resisters because of their prolonged survival under antibiotic selection (18) , especially when there is an accompanying increase in mutation rates (19) or competence levels (20) . Exacerbating the problem, diverse conditions that bacteria face in the host can trigger phenotypic resistance (21) in the form of MIC shifted resistance, tolerance, and/or high persistence. Triggers include stresses imposed by substerilizing host immunity, such as nutrient and micronutrient limitation, reactive oxygen and nitrogen species, hypoxia, and low pH. Equally challenging, infecting bacteria may develop phenotypic resistance when they encounter subinhibitory concentrations of an antibiotic due to its slow penetration or inter mittently waning concentration between doses in certain biological niches. In the standard combination regimens for TB, the distinct pharmacokinetics of each antibiotic ensure that mycobacteria in pul monary cavities are exposed to subinhibitory antibiotic concentra tions of each member of the combination for hours each day (22) . Such patterns of exposure can induce phenotypic resistance not only to the triggering drug but also to unrelated ones (23) . This can reduce treatment efficacy, extend treatment duration, and foster emergence of genetic MICshifted resistance. Highsurvival (HS) mutants ( Fig. 1) , which display tolerance (24, 25) and/or high persistence (13) , have provided a powerful route to un covering mechanisms of phenotypic resistance. In addition, such mutations have been identified in clinical isolates during or after antibiotic treatment (26, 27) and have been shown to precede muta tions that lead to genetic MICshifted resistance both in vitro (18) and in patients (28) . However, the systematic isolation of these mutants poses challenges. Here, using the model mycobacterium Mycobacterium smegmatis (Msm) and extending results to Mtb, we introduce a facile forwardgenetic method-applicable to any culturable bacterial spe cies, such as those flagged by the World Health Organization as top priorities for the development of new antibiotics-for isolation of mutants that have markedly increased tolerance and/or persistence to a given antibiotic. We found that loss of function of ArgA or ArgD, dispensable members of the essential arginine biosynthesis pathway in Msm, confers both tolerance and high persistence to kanamycin through upregulation of the gene encoding the transcriptional regulator WhiB7 and the downstream effector, Eis. Loss of ArgA or ArgD also elicits HS upon exposure to rifampicin and MICshifted resistance to the macrolide clarithromycin, both of which are also conferred by whiB7 up regulation. Our results reveal that perturbation of an essential pathway can trigger multiple forms of resistance to antibi otics targeting other pathways. These findings have major implications for antibiotic therapy in three respects. Regimens should be designed so that no component induces phenotypic resistance to the others. Targets that are poor ly vulnerable should be avoided, as the partial inhibition typically achieved by an antibiotic is likely to trigger phenotypic resistance mechanisms rather than killing the pathogen. Last, WhiB7 emerges as a target whose inhibition might increase the efficiency and effi cacy of antibiotic regimens for mycobacterial diseases. The systematic isolation of HS mutants without an increase in MIC, which comprise mutants that display tolerance and/or high per sistence, is challenging because they are difficult to separate from MICshifted genetic resisters that emerge during antibiotic exposure. To overcome this problem, we developed a fourstep in vitro method that allows for spatiotemporal separation of genetic MICshifted resisters from survivors without an increase in MIC, including both HS mutants and wildtype (WT) persisters, thereby permitting isolation and sub sequent validation of HS mutants from a genetically heterogeneous bacterial population ( Fig. 2A) . In the first step, survivors of antibiotic exposure are isolated. A large number of bacteria (~10 7 ) are seeded onto a filter that is then placed onto an agar plate containing 10× the MIC of an antibiotic (fig. S1A). Bacteria are exposed to the antibiotic for a period of time predetermined to kill approximately 99.9999% of a WT population ( fig. S1B ). During the exposure period, genetic MICshifted resisters with MIC > 10fold grow and will form visible colonies on the filters given sufficient incubation time, while genetic MICshifted resisters with MIC between 2 and 10fold and non-MICshifted survivors cannot form visible colonies. Next, the filter is transferred to an agar plate containing 2× the MIC of the same antibiotic. Genetic MICshifted resisters with MIC between 2 and 10fold now grow and form visible colonies given sufficient incubation time. Last, the filter is transferred to an agar plate containing 0.4% charcoal for 24 hours to remove residual antibiotic without affecting cell viability (29) before final transfer to a plate of growthpermissive agar for recovery of candidate non-MICshifted survivors, which grow as spatially isolated colonies. Colonies generated from non-MICshifted survivors are distinguished temporally from those formed by genetic MICshifted resisters by their late emergence, i.e., only during the recovery phase. In the second step of the method, colonies that emerged during recovery are picked and outgrown in liquid medium, and their sus ceptibility to the antibiotic is tested to confirm the absence of an increase in MIC compared to the WT. Cultures confirmed to have arisen from non-MICshifted survivors can be WT persisters or har bor HS mutations. These two cases are distinguished in the third step by screening cultures for an increase in survival relative to the WT. Equal volumes of cultures diluted to the same optical density (OD) are seeded onto separate filters, and filters are placed onto an agar plate con taining 10× the MIC of the antibiotic as in the first step of the meth od. After the exposure period, filters are transferred to agar plates with charcoal for 24 hours and then to growthpermissive agar plates for recovery. After recovery, the number of surviving bacteria is com pared to that of a WT control (which typically has a number of sur vivors on the order of 10 0 to 10 1 ; see fig. S1B). Candidates with an increased number of survivors in at least two independent filter exper iments qualify as HS mutants. In the final step, the genomes of con firmed HS mutants are sequenced to identify candidate HS mutations. Loss-of-function mutations in ArgA and ArgD lead to three types of resistance to antibiotics with distinct targets in Msm We used this method to isolate HS mutants from a WT population of Msm, which we assumed would contain spontaneous mutants that may display an HS phenotype; details of the screen are shown in table S1. Using the aminoglycoside kanamycin, which inhibits protein syn thesis by binding to the 30S ribosomal subunit, as the exposure anti biotic, we recovered nine mutants with mutations in genes belonging to the arginine biosynthesis pathway: one in argA (MSMEG_2691) and eight in argD (MSMEG_3773) (Fig. 2 , A and B, and table S2). In addition to a large increase in survival upon exposure to kanamycin, the mutants had increased survival when exposed to additional ami noglycosides, including amikacin and streptomycin, and to rifampicin, which targets the RNA polymerase RpoB (Fig. 2C shows ArgDE105X as a representative argD mutant; the seven other argD mutants are shown in fig. S1C ). In contrast, these mutants did not show increased survival when exposed to levofloxacin or meropenem, which respec tively target DNA gyrase and penicillin binding proteins ( Fig. 2C and fig. S1C ). We confirmed that the MIC of all antibiotics for which the mutants had an HS phenotype was unchanged compared to the WT ( fig. S2A) . A quantitative kill curve performed in liquid medium con taining kanamycin showed that the mutants exhibited both a slowed kill rate for the bulk population (genetic tolerance) and a proportion of persister cells five to six orders of magnitude higher than the WT (high persistence) after 12 hours of antibiotic exposure, which is when the WT kill curve starts to reflect the slow kill rate of the persister popula tion (Fig. 3A) . The mutants displayed a third type of resistance-genetic MICshifted resistance-to the macrolide clarithromycin ( Fig. 3B) , which binds to the 50S ribosomal subunit to inhibit protein synthesis. Because many of the mutations were frameshifts, we suspected that all of them led to loss of function. To test this, we transformed the argA and argD mutants with anhydrotetracycline (atc)-inducible (teton) copies of WT argA and argD, respectively. Growing the teton strains in the presence of atc complemented the increase in survival upon exposure to kanamycin (Fig. 3C) , genetic MICshifted resistance to clarithromycin ( fig. S2B ), and the growth defect exhibited by the FS6 and E105X mutants (Fig. 3D) , whose respective generation times were 1.51 and 1.62 times longer than that of the WT when grown in 7H9 medium ( fig. S2C ). To further test whether loss of ArgA or ArgD function was responsible for the resistance phenotypes of the argA and argD mutants, we constructed a genetic knockout strain for each gene ( fig. S2D ) and showed that these strains recapitulated the HS ( Fig. 3C and fig. S2 , A and E) and genetic MICshifted resistance phenotypes ( Fig. 3B and fig. S2F ) as well as the growth defect ( Fig. 3E and fig. S2C ) of the mutants in an ArgA or ArgDcomplementable manner. In addition to clarithromycin, loss of ArgA or ArgD function also conferred MICshifted resistance to the macrolides azithromycin and erythromycin ( fig. S2, G and H) . Provision of l-arginine complements the resistance phenotypes of the argA and argD mutants Because ArgA and ArgD are involved in arginine biosynthesis, we measured larginine levels in the argA and argD mutants to de termine whether arginine deficiency might play a role in the resistance phenotypes. Neither strain had an arginine level significantly differ ent from that of the WT ( fig. S3A ), most likely due to recruitment of other enzymes to replace the functions of ArgA and ArgD. Such recruitment could reflect and/or result in transcriptional and other changes that could lead to the resistance phenotypes observed. Pro vision of exogenous larginine might forestall those changes, pre sumably by shutting down the arginine biosynthesis pathway, and complement the resistance phenotypes. Genetic tolerance and high persistence to kanamycin were complemented by growing the mutants in medium supplemented with 1 mM larginine (Fig. 3 , A and C), but not darginine or llysine ( fig. S3B ). Provision of larginine also re versed genetic MICshifted resistance to clarithromycin (Fig. 3B ) and HS upon exposure to rifampicin ( fig. S2E ) and restored a WT growth rate ( fig. S3C ). To understand the kinetics of complementation of the HS phenotype by larginine, we grew the ArgAFS6 mutant in medium supplemented with 1 mM larginine for varying lengths of time before seeding filters and exposing them to kanamycin. We found that between 14 and 24 hours of growth in medium supplemented with larginine was required for maximum complementation of the HS phenotype ( fig. S3D ). In contrast, the growth phenotype was complemented within 1 hour of placing bacteria into medium sup plemented with 1 mM larginine ( fig. S3C ). This result suggested a dissociation between the HS and growth phenotypes. We used the ArgDE105X::teton argD strain to further investigate whether the HS and growth phenotypes could be dissociated. We grew this strain in medium with varied concentrations of atc and tested the survival upon exposure to kanamycin and the growth rate at each concentration. A low concentration of atc (0.8 ng/l) re stored growth rate to that of the WT but did not complement the HS phenotype (Fig. 4A ). In addition, the ArgDE105X mutant grew at the same rate as the WT in Sauton's, a defined minimal medium (Fig. 4B ), but still displayed HS upon exposure to kanamycin (Fig. 4C ). Further, in contrast to reports that observed an inverse relationship between growth rate and phenotypic resistance to antibiotics (30) (31) (32) , WT Msm grown in Sauton's had a generation time 1.42 times longer than that of the WT grown in 7H9 ( Fig. 4B and fig. S2C ) and com parable to the generation times of the FS6 and argA mutants in 7H9 ( fig. S2C ) but did not display increased phenotypic resistance to ka namycin (Fig. 4C) . Together, these results demonstrated that slow growth is neither necessary nor sufficient for HS upon exposure to kanamycin in mycobacteria. Given reports that metabolic inactivity can protect bacteria from antibiotic lethality (33), we next wondered whether a generalized de crease in metabolic activity could underlie the resistance phenotypes in our mutants. We extracted metabolites from WT Msm, the argA and argD mutants, and their respective complemented strains and compared the levels of 40 metabolites (provisionally identified based on accurate mass and retention time) that represented diverse meta bolic categories, including the arginine biosynthesis pathway, central carbon metabolism, proteinogenic amino acids, amino acid precur sors and derivatives, redox molecules, nucleosiderelated molecules, and cofactorrelated molecules (Fig. 4D ). Outside of molecules in the arginine biosynthesis pathway, the levels of no metabolites were decreased more than twofold compared to the WT in either mu tant (Fig. 4 , D and E, and data S1). Metabolic blocks could lead to accumulation of metabolites in blocked pathways; the levels of only two metabolites outside of the arginine biosynthesis pathway in the argA mutant and three in the argD mutant were increased more than twofold compared to the WT (Fig. 4 , D and E, and data S1). To complement our metabolomics findings, we measured respiratory activity using a resazurin assay, in which the nonfluorescent molecule resazurin is converted to the fluorescent product resorufin during bacterial respiration (34) . Compared to WT Msm, the argA and argD mutants respectively displayed 1.22 and 1.13fold higher metabolism of resazurin (Fig. 4F ), indicative of increased rather than decreased respiration. Together, these results showed that the resistance phenotypes in the argA and argD mutants were not associated with a generalized decrease in metabolic activity. argA and argD mutants overexpress genes encoding the transcriptional regulator WhiB7 and members of its regulon, including the aminoglycoside-modifying enzyme Eis To obtain mechanistic insight into the resistance phenotypes, we analyzed the transcriptomes of the argA and argD mutants and a WT Msm control grown without or with provision of 1 mM larginine, corresponding respectively to a condition in which the mutants dis played resistance phenotypes and a condition in which the phenotypes were complemented ( fig. S4A ). In the WT control, the expression levels of only three genes differed by more than fourfold with versus without provision of larginine ( fig. S4B and data S2). In contrast, expression levels of 83 genes in the argA mutant and 104 genes in the argD mutant differed by more than fourfold between conditions Fig. 4 . HS upon exposure to kanamycin is not a consequence of slow growth or generally decreased metabolic activity. ns, not significant; *P < 0.05; ***P < 0.001; ****P <0.0001. Error bars: ±SD. (A) ArgD-E105X with an atc-inducible copy of WT argD (E105X::argD) was grown in 0, 0.8, or 25 ng/ml of atc. Left: Growth curves. Symbols, mean OD 600 of two to three replicates. Right: Growth rate relative to WT mean [bars, means of four to five replicate cultures (symbols) pooled from two independent experiments] and kanamycin survival (filters above bars). Generation times compared to WT by one-way analysis of variance (ANOVA). Growth curves and filters representative of two independent experiments. (B) Generation times of WT versus ArgD-E105X in Sauton's (unpaired two-tailed t test). Bars, means of N independent experiments (symbols; N = 5 for WT and 3 for E105X) with three to four replicates each. (C) Kanamycin survival of WT and ArgD-E105X in Sauton's. Representative of four to five independent experiments (E105X in Sauton's, 4; WT in Sauton's versus 7H9, 5). (D and E) Metabolites from argA, argA::argA, argD, and argD::argD provisionally identified by accurate mass and retention time. (D) Colors reflect mean log 2 FC relative to WT from three independent experiments (three replicates each). N-A-l-Glu-5-SA, N-acetyl-l-glutamate-5-semialdehyde; deoxy-MTA, deoxy-methylthioadenosine; SAM, S-adenosylmethionine. (E) Mean log 2 FC compared to a theoretical mean of 0 (two-tailed one-sample t test). Dotted lines, cutoffs (significance, P = 0.05; FC, ±2). (F) Strains from (D) were incubated with resazurin. Fluorescence (excitation 544 nm, emission 590 nm) was normalized to OD 600 before addition of resazurin and then to WT mean. Bars, means of eight replicate cultures (symbols) pooled from two independent experiments (exp.). Means compared to a theoretical mean of 1 (two-tailed one-sample t test). HK, heat-killed. See also data S1. ( Fig. 5A and data S2). Among genes whose expression was increased more than fourfold with provision of larginine, the two mutants had only seven in common, including three in common with the WT (Fig. 5B ). In contrast, among genes whose expression was increased more than fourfold without provision of larginine, the mutants had 46 in common (Fig. 5B ). This suggested that genes expressed in response to loss of either ArgA or ArgD could underlie the resistance phenotypes. Three other genes in the arginine biosynthesis pathway-argC, argB, and argJ-were among the 46 highly expressed in both mutants without provision of larginine, suggesting activation of the pathway. Genes encoding the transcriptional regulator WhiB7 (MSMEG_1953) and members of its regulon were also highly expressed; 35 of the 46 genes, plus 23 additional genes upregulated at least twofold in both mutants, are part of the Msm WhiB7 regulon (Fig. 5B and data S2) (35) . WhiB7 is a member of the WhiBlike family of transcriptional regulators, which are unique to actinomycetes and contain four con served cysteine residues involved in the binding of ironsulfur clusters (36, 37) . WhiB7 has an AT (adeninethymine)hook domain that enables it to bind ATrich DNA sequences in the promoters of the genes in its regulon (36, 37) . The WhiB7 regulon includes WhiB7 itself in addition to genes encoding efflux pumps and enzymes that modify antibiotics or their targets; deletion of whiB7 renders myco bacteria more susceptible to ribosometargeting antibiotics (35, 36, 38) . We therefore hypothesized that overexpression of WhiB7 mediated the resistance phenotypes for aminoglycosides, rifampicin, and clarithromycin observed in our mutants. Among WhiB7 regulon members upregulated in our mutants, we hypothesized that the aminoglycosidemodifying enzyme Eis (MSMEG_3513) was responsible for mediating HS upon exposure to aminoglycosides. We confirmed increased expression of whiB7 and eis in the argA and argD mutants and complementa tion of expression levels of both genes upon provision of larginine by quantitative reverse transcription polymerase chain reaction (qRT PCR) (Fig. 5C ). Mutations upstream of whiB7 and/or eis confer HS upon exposure to aminoglycosides or rifampicin and MIC-shifted resistance to clarithromycin Our hypothesis that whiB7 and/or eis overexpression mediated the re sistance phenotypes to aminoglycosides, rifampicin, and clarithromycin was supported by an evolution experiment designed to select for (35) . The >2-fold category is exclusive of transcripts induced >4-fold in both mutants. (C) whiB7 and eis transcript levels in the argA, argD, and WT strains grown ± provision of 1 mM l-arginine. Bars, mean log 2 fold change relative to WT of three replicates (symbols). Error bars, ±SD. Cp values compared to WT Cp (one-way ANOVA). **P < 0.01; ****P < 0.0001. Representative of two independent experiments. See also fig. S4 and data S2. mutants in the argA and argD backgrounds for which HS upon exposure to kanamycin was no longer complemented by provision of larginine (Fig. 6A) . We grew the mutants in medium containing larginine such that they would have a WT level of survival when ex posed to kanamycin. Next, we subjected them to cycles of kanamycin exposure until survival increased, indicating emergence of a mutation that prevented complementation of the HS phenotype by larginine or conferred HS de novo. The genomic sequences of four mutants isolated from cultures with an HS phenotype despite provision of larginine (Fig. 6B ) contained mutations in either the 5′ untranslated region (5′UTR) of whiB7 (39) or the putative promoter region of eis ( Fig. 6C and table S2 ), which contains a 5-base pair (bp) ATrich region starting 45 bp before the annotated start codon that may constitute the WhiB7 binding site (Fig. 6C) . Moreover, two additional HS mutants that we isolated on kanamycin along with the argA and argD mutants in our initial screen also had mutations in the 5′UTR of whiB7 ( Fig. 6C and table S2). We dubbed these HS mutants ups_wm1 and ups_wm2 for upstream whiB7 mutant. Similar to the argA and argD mutants, both ups_wm1 and ups_wm2 displayed HS upon exposure to kanamycin, amikacin, streptomycin, and rifampicin ( Fig. 6D and fig. S5A ), for which their MICs were within 2.25fold that of the WT ( fig. S5B ), well below the concentration used in the plates for the HS assay. They also exhibited genetic MICshifted resistance to clarithromycin, azithromy cin, and erythromycin ( Fig. 6E and fig. S5 , C and D). We hypothesized that the mutations in the four cycling mutants and two additional HS mutants resulted in constitutive overexpres sion of the downstream gene to confer resistance. We cloned whiB7 from the ups_wm1 and ups_wm2 HS mutants as representatives of the whiB7 5′UTRmutated strains along with the 485bp region up stream, which contains the WhiB7 binding site and complete 5′UTR [ Fig. 6C , as described in (39)]. We also cloned eis along with the 236 bp, preceding it from the evolution experiment mutant with a mutation upstream of eis (ups_e-m for upstream eis mutant). Upon trans forming these constructs into WT Msm, all transformants displayed HS upon exposure to kanamycin (Fig. 6D) and amikacin (fig. S5A ). In addition, the ups_w transformants displayed HS upon exposure to rifampicin (Fig. 6D ) and genetic MICshifted resistance to clarithro mycin (Fig. 6E) . MICs for the three strains were within 2.25fold of the WT MICs for the antibiotics upon exposure to which the strains dis played HS ( fig. S5B ), again well below the concentrations used in the HS assay. The strains all had a WT growth rate (Fig. 6F ), further sup porting our evidence that slow growth is not required for the whiB7and/or eismediated HS phenotypes. We confirmed overexpression of whiB7 and eis for the two HS mutants with mutations upstream of whiB7 by qRTPCR (Fig. 6G) . These results demonstrated that muta tions upstream of whiB7 or eis confer HS upon exposure to amino glycosides and that mutations upstream of whiB7 additionally confer HS upon exposure to rifampicin and genetic MICshifted resistance to macrolides, most likely by mediating constitutive overexpression of other members of the WhiB7 regulon, such as efflux pumps. Differ ences in expression level of the specific direct effectors or in efficiency of drug neutralization by these effectors likely underlie differences in the types and strengths of resistance phenotype observed for each drug. Deleting whiB7 or eis in the argA and argD backgrounds abolishes HS upon exposure to kanamycin To further test whether whiB7 and/or eis overexpression were me diators of HS upon exposure to kanamycin in the argA and argD mutants and evaluate whether there were additional contributors, we deleted either whiB7 or eis in the argA and argD backgrounds to create argAwhiB7, argAeis, argDwhiB7, and argDeis doubledeletion strains ( fig. S5E ). HS upon exposure to kanamycin was abolished with the deletion of either whiB7 (Fig. 6H) or eis (Fig. 6I) . We complemented the eis strains with ups_ewt but were unable to complement the whiB7 strains with ups_wwt containing 485 bp upstream of whiB7 ( fig. S5F) , suggesting that this construct may be missing uncharacterized regulatory elements important for up regulation of whiB7 in the context of the argA and argD mutants. We achieved complementation with a longer construct beginning 800 bp upstream of the whiB7 start codon (ups800_wwt). However, complementation was not seen in every experiment and was more complete in the argAwhiB7 mutant compared to the argDwhiB7 mutant, suggesting the existence of additional regulatory factors at the promoter level or at posttranscriptional or posttranslational levels that may differ among experiments and between the two strains. Nei ther the ups800_wwt ( fig. S5G ) nor the ups_ewt construct (Fig. 6D ) conferred an HS phenotype on the WT. Together, these results demon strated that eis was the sole direct mediator of HS upon exposure to kanamycin in the argA and argD mutants. To investigate whether disruption of arginine biosynthesis would con fer HS upon exposure to aminoglycosides in Mtb, we constructed an argD (rv1655) Mtb mutant ( fig. S6A) . We chose to construct the argD mutant since we had obtained a larger diversity of mutations in this gene in Msm compared to argA, which suggested that sponta neous mutations may arise more frequently in this gene, making it potentially more relevant to HS in physiological contexts. Unlike the Msm argD mutant, the Mtb argD mutant was an arginine auxotroph (Fig. 7A) , and this auxotrophy was bactericidal (Fig. 7B) , consistent with what has been reported for Mtb argB and argF mutants (40) . To minimize killing due to auxotrophy in experiments to test the survival of the mutant upon exposure to antibiotics, we assessed the killing kinetics of a panel of aminoglycosides for which the Msm E105X mutant displayed HS ( fig. S6B ) to determine which produced the fastest killing of WT Mtb ( fig. S6C ). On the basis of the results, we chose exposure to gentamicin at a concentration equivalent to ~15× the MIC ( fig. S6D ) for 14 days. To test survival of the argD mutant upon exposure to gentamicin, we washed cultures of the mutant grown with provision of 1 mM larginine, resuspended in medium without larginine supplementation, and seeded filters after 4 days of argi nine starvation, a window within which we did not observe death from arginine auxotrophy (Fig. 7B) . The Mtb argD mutant displayed a statistically significant increase in survival upon exposure to gen tamicin that was complemented by constitutively expressed argD, although the effect size was smaller than for the Msm argA and argD mutants (Fig. 7, C and D) . The increase in survival was comple mented by growth in 1 mM larginine in two of three experiments. Over an exposure period of 14 days, the viable Mtb argD mutant population would be expected to decrease by two log 10 from auxot rophy alone (Fig. 7B) ; thus, the argD mutant displayed increased survival despite substantial loss of viability from arginine depriva tion. Similar to the Msm argA and argD mutants, the Mtb argD mutant also overexpressed both whiB7 (rv3197A) and eis (rv2196) (Fig. 7E) , demonstrating that perturbation of arginine biosynthesis leads to whiB7 upregulation in Mtb and suggesting that whiB7 and eis could also be the mediators of the HS phenotype in Mtb. Given the potential clinical relevance of increased survival upon ex posure to aminoglycosides, which are used to treat Mtb infections resistant to firstline antibiotics, we investigated whether clinical isolates harbor mutations in argD. Among 710 clinical isolates from patients in China (41, 42) , 25 strains (3.5%) had missense (13 strains) or syn onymous (12 strains) mutations in argD (Fig. 7F and table S3 ). Al though synonymous mutations would not be expected to affect protein function, they could affect expression, e.g., due to introduc tion of rare codons. Since HS mutations may precede the emergence of genetic MICshifted resistance (18, 28) , we quantified the pro portion of strains displaying genetic MICshifted resistance to ka namycin, streptomycin, and/or rifampicin, three antibiotics for which we observed a strong HS phenotype in our Msm mutants, among strains with and without mutations in argD. A greater proportion of strains with mutations in argD had genetic MICshifted resistance to kanamycin (8% versus 6.8%), streptomycin (52% versus 41%), and/or rifampicin (64% versus 57%) (Fig. 7F) , suggesting trends that could potentially achieve statistical significance with larger sample sizes. To this end, we searched the Genomebased Mycobacterium tuberculosis Variation Database (43) , which contains 2819 genomic sequences of Mtb isolates from around the world, the majority are from Russia (38%) or Malawi (35%). We found a total of 111 single nucleotide polymorphisms (SNPs), including 68 missense and 43 synonymous mutations (Fig. 7F and table S4) , and 16 indels in argD ( Fig. 7F and table S5) . Assuming that all are in unique strains, this represents 4.5% of the total number of strains in the database, a sim ilar proportion to that in the 710 clinical isolates from China. We found a statistically significant enrichment for genetic MICshifted resistance to kanamycin (3.9% versus 1.5%; P = 0.036) among strains with mutations in argD compared to strains without mutations (Fig. 7F) . Given our results showing that ArgD function is essential in vitro, the SNPs in these clinical isolates may represent mutations that do not completely abrogate the aminotransferase function of ArgD. Alternatively, some of these mutations may abolish ArgD func tion, as the existence of indels suggests that Mtb can scavenge argi nine from the human host despite its apparent inability to do so in mice (40) ; if so, then the amount it scavenges could be sufficient to prevent death from auxotrophy but insufficient to complement HS induced by loss of ArgD function. Overall, these findings demon strate that argD mutations are present in diverse Mtb clinical isolates and that strains bearing them are enriched for genetic MICshifted re sistance, suggesting that these mutations may have clinical relevance. We developed a powerful method for the isolation of HS mutants and used it to uncover mutants in mycobacteria with defects in the arginine biosynthesis pathway that display three forms of resistance to antibiotics targeting other pathways, a finding that has implica tions for developing antibiotics and using them in combination. The predominant approach for isolation of HS mutants relies on cyclic exposure of mutagenized bacterial populations to one or more anti biotics in liquid culture with outgrowth periods in antibioticfree medium between cycles and monitoring of the survival fraction via separate liquid exposure assays at various intervals. After an increase in survival fraction is detected, individual mutants are isolated as colonies by plating on solid agar, grown in liquid medium, and indi vidually tested for an increase in survival upon antibiotic exposure (13, (44) (45) (46) (47) . Although this approach has facilitated identification of HS mutants in several species, including Mtb (44), its limitations have likely hindered the discovery of HS mutants on a larger scale. If only one antibiotic is used for the exposure cycles, then genetic MIC shifted resisters can emerge and overwhelm a liquid culture. A com bination of antibiotics is often used to prevent genetic MICshifted resistance (44, 45) , but this precludes discovery of mutants with HS specific to a single antibiotic, which could have clinical relevance. In addition, mutants with fitness defects in antibioticfree conditions may be lost during outgrowth, and this approach requires an addi tional step on solid agar after cycling in liquid to isolate individual mutants. Moreover, testing HS candidates for an increase in survival by liquid exposure assay is labor intensive, requiring removal of the antibiotic via several rounds of washing, plating of serial dilutions on solid agar, and enumeration of colonyforming units (CFUs). The method presented here circumvents these problems. Spatiotempo ral separation of cells that survive antibiotic exposure on the filter surface means that growth of genetic MICshifted resisters does not affect detection of non-MICshifted survivors, including HS mutants. Outgrowth on the filter as spatially separated colonies also prevents loss of mutants with fitness defects, allowing recovery of a wider va riety of mutants, and eliminates the need for an extra step to isolate them. After recovery, the survival phenotypes of individual candi dates can be assessed in a few quick steps-filter seeding followed by two plate transfers-permitting rapid screening of large numbers of candidates. These advantages coupled with flexibility in the size and format of the input bacterial population, drug concentration, and exposure time suit the method to a variety of applications with any culturable microorganism. Our screen for HS mutants in mycobacteria revealed that over expression of whiB7, either through loss of ArgA or ArgD function or through mutation in the whiB7 5′UTR, led to genetic tolerance, high persistence, and genetic MICshifted resistance to antibiotics with distinct targets. Antibiotic tolerance and persistence are often associated with slowed or halted replication and/or reduced meta bolic activity (16, 30, 32, 33, (48) (49) (50) (51) (52) (53) (54) . This is sometimes interpreted as a mechanistic explanation for reduced lethality of the antibiotic, the inference being that processes targeted by the antibiotic are less ac tive during slow growth or inactive when replication is arrested and are thus not susceptible to inhibition. However, actively replicat ing cells, including mycobacteria, can exhibit antibiotic persistence (7, (55) (56) (57) . Here, we provide further compelling evidence that neither halted replication, slowed replication, nor slowed metabolism is re quired for HS by tolerance or persistence. The slower growth imposed by loss of ArgD function was not related to HS upon exposure to kanamycin, and neither the argA nor the argD mutant showed a generalized decrease in metabolic activity. Moreover, strains over expressing whiB7 and/or eis due to upstream mutations displayed HS upon exposure to aminoglycosides and rifampicin but had a WT growth rate. HS in these strains and the argA and argD mutants relied on overexpression of WhiB7 and Eis, a mechanism that does not depend on nonreplication or slowed metabolism. Thus, our re sults support a growing recognition that specific alterations in cellu lar metabolism, rather than general slowing or cessation of metabolic activities, can mediate mechanisms of tolerance and persistence in mycobacteria that may be clinically relevant. Identification of spe cific mechanisms that confer tolerance and persistence, such as the one described here, could help guide discovery of compounds that prevent these types of resistance. Our findings both support and extend the recent evidence from Lopatkin et al. (58) that "metabolic adaptation may represent a class of resistance mechanisms." In that study, mutations in Escherichia coli genes serving central carbon metabolism conferred MICshifted resistance to antibiotics of diverse classes. In the one case studied in depth, this was associated with slowed metabolism (58) . In our studies, mutations in mycobacteria in a metabolic pathway not only con ferred resistance to antibiotics of multiple classes but also conferred three different forms of resistance-MICshifted resistance, genetic tolerance, and high persistence-and this was not attributable to slowed growth or decreased metabolism. An open question raised by our work is how whiB7 expression is triggered by loss of ArgA or ArgD. Expression of whiB7 has been linked to other amino acid biosynthetic enzymes: Constitutive ex pression of MSMEG_4060, a putative aspartate aminotransferase, prevents antitermination in the 5′UTR of whiB7 in Msm, thereby repressing whiB7 expression (59) . Further, MSMEG_0688, a mem ber of the whiB7 regulon that is likely to be an alanine aminotrans ferase (60) , amplifies the expression of whiB7, and MSMEG_6017, likely an alaninevaline aminotransferase (60), represses it (61) . The mechanisms behind these interactions remain to be elucidated, but, combined with the results presented here, they point to a general link between amino acid biosynthetic pathways and regulation of whiB7 expression, likely through induction of metabolic shifts. WhiB7 activity is enhanced in reducing, but not oxidizing, conditions (39) . Perturbations in amino acid biosynthetic pathways might invoke redox changes that could activate low levels of WhiB7 protein con stitutively present in the cell, leading to amplification of whiB7 ex pression via autoinduction. In support of this, deleting argB or argF in Mtb results in both oxidative stress and upregulation of whiB7 (40) , although this appears to be opposite to the conditions that have been shown to favor WhiB7 activity (39) . In addition, the arginine repressor ArgR, which might function as an activator of the argi nine biosynthesis pathway (62) , could regulate expression of whiB7; in support of this hypothesis, ArgR from Streptomyces coelicolor has been reported to bind to ARG boxes present upstream of whiB (63, 64) , the ortholog of mycobacterial whiB2 (37) . Future work will focus on elucidating the mechanism of whiB7 activation following loss of ArgA or ArgD. Previous reports in Msm and Mtb have shown that whiB7 mutants are more susceptible to ribosometargeting antibiotics (36, 38, 39) . Overexpression of WhiB7 and/or Eis in Mtb due to upstream muta tions has been associated with genetic MICshifted resistance to amino glycosides (65, 66) , in Msm, and induction of whiB7 expression via exposure to subinhibitory concentrations of macrolides or the amino acid analog acivicin results in MICshifted resistance to macrolides, including clarithromycin (39), as we observed in our mutants. Here, we show that WhiB7 can additionally mediate tolerance and high per sistence to aminoglycosides. We further link WhiB7 to resistance to rifampicin in the form of non-MICshifted HS, demonstrating that WhiB7 affords protection against non-ribosometargeting antibiotics. In addition to strong WhiB7mediated HS phenotypes for argA and argD mutants in Msm, we showed a smaller but significant pheno type for the argD mutant in Mtb upon exposure to the aminoglycoside gentamicin despite loss of viable cells to arginine auxotrophy, and we documented whiB7 upregulation in this strain. Further, we found argD mutations in the genomic sequences of Mtb clinical isolates. We speculate that some of these mutations might partially disrupt func tion of ArgD in a way that allows synthesis of sufficient arginine to avoid auxotrophy while activating whiB7 expression to elicit an HS phenotype. The lethality of starvation for larginine combined with the appar ent inability of Mtb to scavenge the amino acid from murine hosts (40) has prompted interest in the larginine biosynthesis pathway as a target for new TB drugs (40, 67) . The work we present here suggests that caution should be taken in developing inhibitors of this pathway for therapeutic use. Partial inhibition of enzymes in the arginine biosynthesis pathway, as would be expected for pharmaceutical in terventions, might lead not to death of the bacilli but rather to in duction of phenotypic resistance in the form of HS upon exposure to rifampicin and aminoglycosides, important components of first and secondline therapy for TB, respectively. Along those lines, whiB7 overexpression and the resulting resistance phenotypes we showed here could be induced in many clinical contexts given the broad range of activators that have been identified, including a wide variety of structurally and mechanistically diverse compounds, subinhibitory concentrations of antibiotics, the transition from exponential to sta tionary phase, low iron, heat shock, hypoxia, and the macrophage like intracellular environment (38, 39, (68) (69) (70) (71) (72) (73) . As suggested by our argA and argD mutants and by a study in Msm that documented upregulation of whiB7 in response to mutations affecting ribosome assembly (74) , it is also possible that mutations in a multitude of pathways could conduce to whiB7 overexpression. Thus, our results suggest that WhiB7 could be an important driver of diverse forms of resistance that could lead to treatment failure in TB and other mycobacterial infections. Development of drugs to target WhiB7 could block these forms of resistance and enhance treatment effi ciency and efficacy. Our results demonstrate a mechanism by which perturbation of an essential metabolic pathway elicits antibiotic resistance. Although metabolic perturbation was achieved by means of genetic mutation in our studies, subinhibitory concentrations of antibiotics could ac complish the same effect, leading to increased phenotypic resistance by WhiB7mediated or other mechanisms. Standard treatment for drugsensitive TB consists of 2 months of treatment with four drugs followed by 4 months of treatment with two of them. The require ment for such a prolonged course of antibiotics may be due, in part, to induction of phenotypic resistance by exposure to subinhibitory concentrations of one or more of the drugs in certain biological niches or during certain phases of treatment. Most current assays to evalu ate drug interactions use growth inhibition as the output metric. Al though these assays can capture phenotypic MICshifted resistance, they are blind to phenotypic tolerance and high persistence. This underscores the need for new assays such as the filter method intro duced here to evaluate the bactericidal potential of drug combinations. Such assays will aid in investigating the extent to which induction of phenotypic resistance occurs with current and proposed treatment regimens for TB. Formulations that minimize induction of pheno typic resistance or inclusion of an agent that blocks this induction might greatly shorten the course of treatment. Strains used in this study are listed in table S6. Msm strains were cultured at 37°C with shaking in Middlebrook 7H9 medium supple mented with 0.2% glycerol, 0.05% tyloxapol, 0.5% bovine serum albu min fraction V, 0.2% dextrose, and 0.085% NaCl. For strains bearing chromosomally integrated antibiotic resistance cassettes, appropri ate antibiotics [hygromycin (50 g·ml −1 ), zeocin (25 g·ml −1 ), and streptomycin (25 g·ml −1 )] were included during strain generation but not in cultures grown for experiments. Mtb strains were cultured in the same way but without shaking. For the Msm experiments con ducted in Sauton's minimal medium, the medium contained 0.05% potassium phosphate monobasic, 0.05% magnesium sulfate hepta hydrate, 0.2% citric acid, 0.005% ferric ammonium citrate, 0.2% glycerol, 0.05% ammonium sulfate, 0.01% zinc sulfate, and 0.05% tyloxapol and was adjusted to pH 7.4 (75) . All plasmids were constructed using Invitrogen Gateway recombination cloning technology. Plasmids are indicated in parenthesis after the strain name in table S6. T10MP1 is an atcinducible mycobacterial promoter (76, 77) , Ptb38 is a constitutive mycobacterial promoter (76) , and pGMCS refers to the pDE43MCS destination vector in Gateway cloning system, which confers streptomycin resistance (77) . Primers used in cloning are listed in table S7. The bottom portion of a Swinnex Filter Holder sized for either 25 or 47mm filters (MilliporeSigma, SX0002500 or SX0004700) was mounted on a 1200cm 3 MediVac Guardian suction canister (Cardinal Health, 65651212). Bacterial cells were deposited on Durapore hydro philic polyvinylidene difluoride (PVDF) membrane filters with a pore size of 0.22 m and a diameter of either 25 or 47 mm (MilliporeSigma, GVWP02500 or GVWP04700) to a final density of approximately 6 × 10 3 CFU/mm 2 . To achieve this density, 1 ml of bacterial culture diluted to OD = 0.03 was seeded onto 25mm filters, and 5 ml of bacterial culture diluted to an OD of 0.02 was seeded onto 47mm filters under the assumption that an OD of 1 is equivalent to a concentration of ~10 8 CFU/ml. See fig. S1A for a schematic representation of the filter seeding process. To isolate non-MICshifted survivors of antibiotic exposure, seeded filters were incubated at 37°C on 7H11 agar plates supplemented with 0.5% glycerol and containing 10× the MIC of an antibiotic for the predetermined exposure time for that antibiotic (table S8) . This phase allowed killing of susceptible cells and emergence of colonies formed by MICshifted resisters with MIC > 10fold. Next, filters were transferred to plates containing 2× the MIC of the antibiotic and incubated for 5 days at 37°C. This step was to allow for emergence of colonies formed by MICshifted resisters with MIC between 2 and 10fold, and an exposure time of 5 days was chosen to allow sufficient time for formation of visible colonies. Filters were then transferred to plates containing 0.4% charcoal and incubated at 37°C for ~24 hours to remove residual antibiotic. Last, filters were trans ferred to 7H11 agar plates supplemented with 0.5% glycerol to allow for growth of any non-MICshifted survivors. To document the emergence of MICshifted and non-MICshifted survivors, photographs of filters were taken after both exposure phases and after recovery. Non-MIC shifted candidates were considered to be those colonies that had emerged during the final incubation phase. Isolated colonies were picked from the filters and grown in 7H9 for further processing. The absence of an increase in MIC for the antibiotic used in the survivor isolation step for cultures grown from colonies that emerged during recovery was confirmed using an abbreviated MIC assay. Two microliters of bacterial culture was inoculated in 200 l of 7H9 supplemented with no antibiotic or 7H9 supplemented with 1× the MIC, 2× the MIC, 4× the MIC, or 10× the MIC of the antibiotic, and OD 600 was read after 2 days of incubation at 37°C. Candidates that displayed growth at higher concentrations of the antibiotic than the WT were considered to be genetic MICshifted resisters and were excluded from further analysis, while candidates displaying WT susceptibility to growth inhibition were considered to have arisen from non-MICshifted survivors. To distinguish candidates that arose from WT persisters from those bearing HS mutations, we grew each candidate plus a WT control to midlog phase in 7H9 and seeded them individually onto filters as described in the "Filter seeding" section. Filters were transferred to 7H11 agar plates supplemented with 0.5% glycerol and 10× the MIC of the antibiotic on which each candidate had been isolated and then incubated at 37°C for the appropriate exposure time (table S8) . Filters were then transferred to 7H11 plates supplemented with 0.5% glycerol and 0.4% charcoal (charcoal plates) for approximately 24 hours at 37°C to remove residual antibiotic before final transfer to 7H11 plates supplemented with 0.5% glycerol (recovery plates). Candidates with a >10fold increase in survivors relative to the WT control were tested again to confirm that the increase was reproducible. Candidates with a level of survival reproducibly >10fold higher than that of the WT were considered to be HS mutants. Filter assay for assessment of survival upon exposure to an antibiotic For Msm strains, bacterial cultures were grown to midlog phase in 7H9 supplemented with any compounds for which the effect on survival upon antibiotic exposure was to be tested or in Sauton's minimal medium. Filters were seeded and processed as described in the "HS candidate screening and verification" section. Photographs of filters were taken after 3 days on recovery plates. To more easily visualize bacterial growth, raw images were changed to gray scale, and the brightness and contrast were adjusted. For each filter image, the same adjustments were applied to the entire image, and all adjustments were linear. For Mtb strains, the procedure was the same except charcoal and recovery plates were supplemented with 1 mM larginine to support the auxotrophic argD strain used in the experiments, and recovery plates were additionally supplemented with 10% OADC (oleic acidalbumin-dextrose-catalase). Photographs of filters were taken after about 20 days on recovery plates. Varied concentrations of each antibiotic were prepared in the appropriate solvent (table S8) by performing twofold serial dilutions. Two microliters of each concentration and the solvent alone were deposited into three rows of a 96well plate per strain to be tested. Bacterial cultures were grown to log phase in 7H9. For Msm, cultures were diluted to an OD of 0.001 or 0.025, and 198µL aliquots were dispensed into wells prefilled with antibiotic. Plates were incubated at 37°C with shaking at 100 rpm for 2 to 3 days. For Mtb, cultures were diluted to an OD of 0.04 and dispensed into wells with antibiotic. Plates were incubated at 37°C without shaking for 9 days. Wells were resuspended before reading the OD 600 . MIC values were calculated in GraphPad Prism using an opensource file (available at www.graphpad.com/support/faq/fittingbacterialgrowthdatato determinethemicandnic/) that calculates the MIC based on a nonlinear regression model developed by Lambert and Pearson (78) . In this method, the MIC is defined as the intersection of the horizontal line projected from the bottom plateau of the curve with a line projected from the inflection point with slope equivalent to the slope of the curve at that point. For Msm, strains were grown in 7H9 or Sauton's minimal medium to midlog phase and then diluted to an OD of 0.05 in 7H9 supplemented with any compound for which the effect on growth was to be tested or in Sauton's. Two to five replicates consisting of 100 l of diluted culture each were added to a 96well plate. A breathable membrane allowing for gas exchange was applied to the plate, which was inserted into a Spark multimode microplate reader (Tecan) set to 37°C. OD 600 readings were taken every 30 min with orbital shaking at 180 rpm between reads. For Mtb, strains were grown in 7H9 (+1 mM larginine for the argD strain) and then diluted to an OD of 0.05 in 7H9 ± 1 mM larginine (argD strain was washed before diluting). Three repli cates consisting of 200 l of diluted culture each were added to a 96well plate. The plate was incubated at 37°C without shaking. To monitor growth, periodic OD 600 readings were taken in a plate reader after resuspending the contents of each well. Msm strains were grown to midlog phase in 7H9 with or without 1 mM larginine. Cultures were diluted in triplicate to an OD of 0.1 in 10 ml of 7H9 with or without 1 mM larginine. An aliquot from each culture was taken and serially diluted, and 10 l of three dilutions was plated on 7H11 agar supplemented with 0.5% glycerol and 0.4% charcoal to enumerate input CFUs. Kanamycin was added to the 10ml cultures to a final concentration of 3.5 g·ml −1 (5× the MIC), and cultures were incubated at 37°C with shaking at 100 rpm. CFUs were enumerated at seven additional time points (~4, 8, 12, 24, 36, 48 , and 60 hours) as described for the input CFUs; addition of charcoal in the plates for CFU enumeration eliminated the need for washing the cultures to remove kanamycin before plating. At later time points, to increase the limit of detection, cultures were concentrated 10 or 100fold by spinning down 100 l or 1 ml of culture, resuspending the pellet in 20 l of 7H9, and plating. Msm strains were grown to midlog phase in 7H9 or 7H9 + atc (250 ng/ml) for complemented strains. Three replicate 25mm PVDF filters (MilliporeSigma, GVWP02500) were seeded with the equivalent of 1 ml of culture at OD 600 = 1 and placed onto 7H11 agar plates supplemented with 0.5% glycerol and atc (250 ng/ml) for complemented strains. Filters were incubated at 37°C for 16 hours before being placed into tubes containing 800 l of 40% acetonitrile, 40% methanol, and 20% H 2 O solution and silica beads. Bacteria were lysed by bead beating (two bead beating cycles separated by 5 min rest; each cycle consisted of three rounds of beating for 50 s at 6500 rpm followed by 30 s rest) in a Precellys 24 tissue homogenizer cooled with a Cryolys cooling unit (Bertin Instruments) to obtain metabolite extracts. Extracts were analyzed using a Diamond Hydride type C column (Cogent) on an Agilent 1200 Infinity liquid chromatography system coupled to an Agilent 6230 timeofflight spectrometer (79) . Metabolite peaks were identified on the basis of accurate mass and retention time and integrated in Agilent MassHunter Qualitative Analysis software. Peak integrations were normalized to residual protein concentration of the metabolite extracts quantified by the BioRad DC Protein Assay kit. Msm strains were grown to midlog phase in 7H9 or 7H9 + atc (250 ng/ml). Cultures were diluted, split into four replicate wells of a 24well plate, and incubated for 2 to 3 hours at 37°C with shaking at 100 rpm. Heatkilled cells were prepared by heating an aliquot of WT Msm culture to 90°C for 40 min. After incubation, OD 600 was measured, and 100 l of the alamarBlue Cell Viability Reagent (Invitrogen, DAL1100) was added to 800 l of culture. Cultures were incubated for 30 min at 37°C with shaking at 100 rpm, then 200 l from each culture was transferred to a clearbottom black 96well plate, and fluorescence at an excitation of 544 nm and emission of 590 nm was measured in a plate reader. Fluorescence readings were normalized to the OD 600 of the cultures immediately preceding addi tion of alamarBlue. Total RNA was extracted from 10 to 20 ml of bacterial culture by washing the cells in guanidinium thiocyanate buffer, bead beating washed pellets into TRIzol, extracting RNA in chloroform, and purifying extracted RNA with the Directzol RNA miniprep kit (Zymo Research, R2052). After elution, DNA was removed from total RNA samples by incubation with TURBO DNase (Ambion, AM2238) at 37°C for 1 hour. Total RNA samples were then repurified using the RNA Clean and Concentrator25 kit (Zymo Research, R1017) for RNA sequencing (RNAseq) samples or the Directzol RNA miniprep kit for qRTPCR samples. Samples for RNAseq were split into two groups of 12: WT Msm (WTD) and argD were cultured in triplicate in 7H9 or 7H9 supplemented with 1 mM larginine (R), and WT Msm (WTA) and argA were cultured the same way. Total RNA was extracted from 20 ml of culture grown to midlog phase as described in the "RNA extraction" section. Ribosomal RNA (rRNA) was depleted from total RNA samples using the RiboMinus Transcriptome Isolation Kit for bacteria (Thermo Fisher Scientific, K155004), and rRNA depleted RNA was concentrated using the RNA Clean and Concentrator25 kit. Indexed RNAseq libraries were prepared from rRNAdepleted RNA samples using the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (New England Biolabs, E7760S) and NEBNext Multiplex Oligos for Illumina Index Primers Set 1 (New England Biolabs, E7335S; contains twelve unique index primers). RNA libraries were purified with AMPure XP Beads (Beckman Coulter, A63881), quality was checked on a Bioanalyzer, and the 12 uniquely indexed libraries in each group were pooled together. Sequencing of the two pools was performed on an Illumina HiSeq4000 instrument by the Genomics Core Facility of the Weill Cornell Medicine Core Laboratories Center. Pairwise differential expression analysis was performed by the Core on the eight conditions (WTD, WTD + R, argD, argD + R, WTA, WTA + R, argA, argA + R; each an average of results from three replicate libraries) to identify genes significantly differentially regulated between each condition. Primers and probes for qRTPCR are listed in table S9. All were designed using the Biosearch Technologies RealTimeDesign qPCR Assay Design Software. Primers were ordered from Invitrogen, and probes were ordered from TIB Molbiol. Specificity of primer/probe sets was tested using a dilution series of genomic DNA from Msm or Mtb. To measure transcript amounts, bacterial cultures (10 ml for Msm, 20 ml for Mtb) were grown in triplicate to midlog phase in 7H9 with or without provision of 1 mM Larginine. For the cultures without larginine supplementation, the auxotrophic Mtb argD strain was grown to midlog phase in medium with 1 mM larginine, washed, resuspended in medium without larginine, and incubated for 4 days. Total RNA was extracted as described in the "RNA extraction" section. cDNA was prepared using 500 ng of RNA as the template for MMuLV reverse transcriptase (New England Biolabs, M0253L), and corresponding noRT reactions were also prepared as a control for residual genomic DNA. Cycling with quantification was performed in a Roche LightCycler 480 instrument. Second derivative analysis was performed in the LightCycler 480 Software (release 1.5.0 SP3) to obtain crossing points (Cp) for each sample for the test genes and an internal control (mysA, MSMEG_2758, for Msm and sigA, rv2703, for Mtb). Statistical analysis was performed on Cp values in GraphPad Prism using an ordinary oneway analysis of variance (ANOVA) test with multiple comparisons. For each test strain or condition, a Cp value was calculated by subtracting the average Cp of the three WT biological replicates from the average Cp of the three test strain/condition replicates. Log 2 fold change values relative to the WT control were calculated as 2 −Cp . In Msm, all genetic knockout strains (argD, MSMEG_3771; argA, MSMEG_2691; whiB7, MSMEG_1953; eis, MSMEG_3513) were produced by allelic exchange. Plasmids were constructed using the temperaturesensitive pXSTS plasmid backbone (80) containing a recombination fragment consisting of ~500 bp upstream of the gene to delete, a resistance cassette (either hygromycin or zeocin), and ~500 bp downstream of the gene to delete. Msm strains were transformed with a plasmid, plated on 7H11 plates supplemented with 0.5% glycerol and either hygromycin (50 g·ml −1 ) or zeocin (25 g·ml −1 ), and incubated for 4 days at 30°C. To select for single crossover transformants, colonies were spotted with 5% pyrocatechol, and yellow colonies were grown at 37°C in 7H9 containing either hygromycin (50 g·ml −1 ) or zeocin (25 g·ml −1 ). To select for double crossover transformants, an aliquot of each culture was spread onto 7H11 agar supplemented with 0.5% glycerol, hygromycin (50 g·ml −1 ) or zeocin (25 g·ml −1 ), and 10% sucrose, and plates were incubated at 40°C. Colonies were spotted with 5% pyrocatechol, and those that remained white were grown in 7H9 supplemented with hygromycin (50 g·ml −1 ) or zeocin (25 g·ml −1 ) and then validated by PCR. The PCRverified strains chosen for use in subsequent experiments were further validated by wholegenome sequencing. In Mtb, the argD strain was constructed by recombinasemediated recombination of a PCR product containing a hygromycin resist ance cassette between sequences homologous to the ~500bp regions upstream and downstream of the argD gene (Rv1655). Mtb H37Rv cells were first transformed with an episomal plasmid containing the phagederived RecET recombinase (pNitrecETsacBkanR) (81) and grown to midlog phase in 7H9 supplemented with kanamy cin (25 g·ml −1 ). RecET expression was induced by addition of isovaleronitrile to 1 M for 24 hours and glycine to 0.2 M for 16 hours. Electrocompetent cells prepared from the induced culture were transformed with 1 g of PCR product and allowed to recover for 24 hours in 7H9 supplemented with 1 mM larginine. Transformants were plated on 7H10 agar supplemented with 0.5% glycerol, 10% OADC, hygromycin (50 g·ml −1 ), and 1 mM larginine. After 16 days of incubation at 37°C, colonies that had emerged were cultured in 7H9 supplemented with hygromycin (50 g·ml −1 ) and 1 mM larginine and then validated by PCR. To select for clones that had lost the pNitrecETsacBkanR plasmid, each validated strain was streaked onto 7H10 agar supplemented with 0.5% glycerol, 10% OADC, 1 mM larginine, and 8.5% sucrose. Sucroseresistant colonies were then patched first onto 7H10 agar supplemented with 0.5% glycerol, 10% OADC, 1 mM larginine, and kanamycin (25 g·ml −1 ) and then onto the same agar without kanamycin. Cultures of kanamycin sensitive strains were grown in 7H9 supplemented with hygromycin (50 g·ml −1 ) and 1 mM larginine to obtain the final Mtb argD strains. The strain chosen for use in subsequent experiments was further validated by wholegenome sequencing. Genomic DNA was isolated from stationary phase cultures by bead beating to break the cells followed by phenolchloroform extraction and ethanol precipitation. Genomic DNA from HS mutants, cycling mutants, Msm argA, Msm argD, and Mtb argD strains was sequenced by the Integrated Genomics Operation at the Memorial Sloan Kettering Cancer Center. Genomic DNA from Msm argAwhiB7, Msm argDwhiB7, Msm argAeis, and Msm argDeis strains was sequenced by BGI Genomics. Genetic knockouts were verified by visually confirming the absence of reads in the area of the expected knockout using the Integrative Genomics Viewer from The Broad Institute. SNPs were identified relative to the National Center for Bio technology Information (NCBI) reference sequence NC_008596.1 for Msm and NZ_CM001515.1 for Mtb. Variant calling files for 710 Mtb clinical isolates associated with studies published by Zhang et al. (41) and Hicks et al. (42) were provided by the Fortune Lab (variants called based on NCBI reference sequence NC_000962.3). Variants in the Genomebased Mycobacterium tuberculosis Variation Database (43) were identified via the webbased interface (information was gathered on 25 September 2020). All statistical tests were performed in GraphPad Prism except for the comparison of proportions of genetic antibiotic resistance be tween Mtb strains with and without argD mutations presented in Fig. 7F . Proportions were compared by calculating the test statistic for comparison of two population proportions Where z is a value on the z distribution; ˆ  1 and ˆ  2 are the proportions with the characteristic of interest in samples 1 and 2, respectively; ˆ  is the proportion with the characteristic of interest in the two samples combined; and n 1 and n 2 are the sizes of samples 1 and 2, respectively. The test was twotailed. Biology of antimicrobial resistance and approaches to combat it Review on AMR -Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations Global tuberculosis report Epigenetic inheritance based evolution of antibiotic resistance in bacteria A novel mechanism of growth phase-dependent tolerance to isoniazid in mycobacteria A non-coding RNA promotes bacterial persistence and decreases virulence by regulating a regulator in Staphylococcus aureus The essential mycobacterial amidotransferase GatCAB is a modulator of specific translational fidelity Posttranslational modification of a histone-like protein regulates phenotypic resistance to isoniazid in mycobacteria The role of metabolism in bacterial persistence Biased partitioning of the multidrug efflux pump AcrAB-TolC underlies long-lived phenotypic heterogeneity Stressed mycobacteria use the chaperone ClpB to sequester irreversibly oxidized proteins asymmetrically within and between cells Treatment of staphylococcal infections with penicillin by intermittent sterilisation hipA, a newly recognized gene of Escherichia coli K-12 that affects frequency of persistence after inhibition of murein synthesis Targeting persisters for tuberculosis control Why is long-term therapy required to cure tuberculosis Bacterial persisters and infection: Past, present, and progressing Evolutionary causes and consequences of bacterial antibiotic persistence Antibiotic tolerance facilitates the evolution of resistance Bacterial persistence promotes the evolution of antibiotic resistance by increasing survival and mutation rates A stress-inducible quorum-sensing peptide mediates the formation of persister cells with noninherited multidrug tolerance Antibiotic persistence as a metabolic adaptation: Stress, metabolism, the host, and new directions Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization Mechanisms of drug-induced tolerance in Mycobacterium tuberculosis Concentration of biochemical mutants of bacteria with penicillin Multiple antibiotic resistance in a bacterium with suppressed autolytic system Persistent bacterial infections and persister cells Bacterial persisters in long-term infection: Emergence and fitness in a complex host environment Effect of tolerance on the evolution of antibiotic resistance under drug combinations Rapid, semiquantitative assay to discriminate among compounds with activity against replicating or nonreplicating Mycobacterium tuberculosis Slow growth determines nonheritable antibiotic resistance in Salmonella enterica Phenotypic variation of salmonella in host tissues delays eradication by antimicrobial chemotherapy The rate of killing of Escherichia coli by -lactam antibiotics is strictly proportional to the rate of bacterial growth Bacterial metabolic state more accurately predicts antibiotic lethality than growth rate Altered Mycobacterium tuberculosis cell wall metabolism and physiology associated with RpoB mutation H526D Mycobacterium abscessus WhiB7 regulates a speciesspecific repertoire of genes to confer extreme antibiotic resistance WhiB7, an Fe-S-dependent transcription factor that activates species-specific repertoires of drug resistance determinants in actinobacteria The actinobacterial WhiB-like (Wbl) family of transcription factors Ancestral antibiotic resistance in Mycobacterium tuberculosis The mycobacterial transcriptional regulator whiB7 gene links redox homeostasis and intrinsic antibiotic resistance Arginine-deprivation-induced oxidative damage sterilizes Mycobacterium tuberculosis Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance Clinically prevalent mutations in Mycobacterium tuberculosis alter propionate metabolism and mediate multidrug tolerance Genome-wide Mycobacterium tuberculosis variation (GMTV) database: A new tool for integrating sequence variations and epidemiology High persister mutants in Mycobacterium tuberculosis Extreme antibiotic persistence via heterogeneity-generating mutations targeting translation Isolation of highly persistent mutants of Salmonella enterica serovar typhimurium reveals a new toxin-antitoxin module A novel point mutation promotes growth phase-dependent daptomycin tolerance in Staphylococcus aureus ATP-dependent persister formation in Escherichia coli Persister formation in Staphylococcus aureus is associated with ATP depletion Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters Internalization of Salmonella by macrophages induces formation of nonreplicating persisters Bacterial persistence as a phenotypic switch Bacterial metabolism and antibiotic efficacy Eradicating bacterial persisters with combinations of strongly and weakly metabolism-dependent antibiotics Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism Dynamic persistence of antibiotic-stressed mycobacteria Revealing the metabolic activity of persisters in mycobacteria by single-cell D2O Raman imaging spectroscopy Clinically relevant mutations in core metabolic genes confer antibiotic resistance Regulatory genes coordinating antibiotic-induced changes in promoter activity and early transcriptional termination of the mycobacterial intrinsic resistance gene whiB7 Aspartate aminotransferase Rv3722c governs aspartate-dependent nitrogen metabolism in Mycobacterium tuberculosis Mapping and manipulating the Mycobacterium tuberculosis transcriptome using a transcription factor overexpression-derived regulatory network ArgR of Streptomyces coelicolor is a pleiotropic transcriptional regulator: Effect on the transcriptome, antibiotic production, and differentiation in liquid cultures ArgR of Streptomyces coelicolor is a versatile regulator Aminoglycoside cross-resistance in Mycobacterium tuberculosis due to mutations in the 5′ untranslated region of whiB7 Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis Novel targets for tuberculosis drug discovery Differential gene expression in response to exposure to antimycobacterial agents and other stress conditions among seven Mycobacterium tuberculosis whiB-like genes Gene expression of Mycobacterium tuberculosis putative transcription factors whib1-7 in redox environments Transcriptional profiling of Mycobacterium tuberculosis exposed to in vitro lysosomal stress Functional genetic diversity among Mycobacterium tuberculosis complex clinical isolates: Delineation of conserved core and lineage-specific transcriptomes during intracellular survival Linking the transcriptional profiles and the physiological states of Mycobacterium tuberculosis during an extended intracellular infection Antagonism between front-line antibiotics clarithromycin and amikacin in the treatment of Mycobacterium abscessus infections is mediated by the whiB7 gene Ribosomal mutations promote the evolution of antibiotic resistance in a multidrug environment Mycobacteria: General culture methodology and safety considerations Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor Construction of conditional knockdown mutants in mycobacteria Susceptibility testing: Accurate and reproducible minimum inhibitory concentration (MIC) and non-inhibitory concentration (NIC) values Mycobacteria Protocols: Second Edition Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/7/35/eabh2037/DC1 View/request a protocol for this paper from Bio-protocol. Competing interests: The authors declare that they have no competing interests. C.N. serves on advisory boards for the Tres Cantos Open Lab Foundation, Tri-Institutional Therapeutics Discovery Institute, Bridge Medicines, Leap Therapeutics, and Pfizer's External Sciences and Innovation. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. All bacterial strains listed in this paper can be provided by C.N.'s or J.V.'s lab pending scientific review and a completed material transfer agreement. Requests should be directed to C.N. at cnathan@med. cornell.edu and J.V. at j.vaubourgeix@imperial.ac.uk.